| Literature DB >> 33602976 |
Donato Santovito1,2,3,4,5,6, Lisa Toto1,7, Velia De Nardis1,2, Pamela Marcantonio1,2, Rossella D'Aloisio7, Alessandra Mastropasqua7, Domenico De Cesare1,2, Marco Bucci1,2,3, Camilla Paganelli1,2,3, Lucia Natarelli5,6, Christian Weber5,6,8,9, Agostino Consoli1,2, Rodolfo Mastropasqua10, Francesco Cipollone11,12,13.
Abstract
Diabetic retinopathy (DR) is a leading cause of vision loss and disability. Effective management of DR depends on prompt treatment and would benefit from biomarkers for screening and pre-symptomatic detection of retinopathy in diabetic patients. MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression which are released in the bloodstream and may serve as biomarkers. Little is known on circulating miRNAs in patients with type 2 diabetes (T2DM) and DR. Here we show that DR is associated with higher circulating miR-25-3p (P = 0.004) and miR-320b (P = 0.011) and lower levels of miR-495-3p (P < 0.001) in a cohort of patients with T2DM with DR (n = 20), compared with diabetic subjects without DR (n = 10) and healthy individuals (n = 10). These associations persisted significant after adjustment for age, gender, and HbA1c. The circulating levels of these miRNAs correlated with severity of the disease and their concomitant evaluation showed high accuracy for identifying DR (AUROC = 0.93; P < 0.001). Gene ontology analysis of validated targets revealed enrichment in pathways such as regulation of metabolic process (P = 1.5 × 10-20), of cell response to stress (P = 1.9 × 10-14), and development of blood vessels (P = 2.7 × 10-14). Pending external validation, we anticipate that these miRNAs may serve as putative disease biomarkers and highlight novel molecular targets for improving care of patients with diabetic retinopathy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33602976 PMCID: PMC7892881 DOI: 10.1038/s41598-021-83047-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379